The participation to the « Spring of Cardiology » offered to Syncrosome the opportunity to present its expertise in the cardiovascular field: development of preclinical models of heart failure and evaluation of cardiac remodelling and function by 2D-echocardiography to assess the efficacy of new therapeutic strategies.
Since 2016, Syncrosome improves it’s expertise in the Cardiovascular field by developing animal models in Heart Failure (Chemical or Surgical induction), in Ischemia Reperfusion Injury, in Pulmonary Arterial Hypertension (Monocrotaline and Sugen model) but also by implanting new devices like the Echocardiography which offers longitudinal follow-up of the animals and add new functional and morphological biomarkers to our cardiovascular studies.
A few words about Syncrosome:
Syncrosome is an Efficacy Characterization CRO and we offer relevant disease models, cutting-edge techniques and a comprehensive background of physiopathology to assist drug discovery companies.
We have developped and validated so far more than 15 disease models, and our flexible and human-sized organization can design and operate tailored experimental protocols to give you appropriate answers.
Our main activities consit in :
- Drug Efficacy Studies in several therapeutic areas :
- Central Nervous Sytem,
- Cardiovascular and Metabolic disease,
- Early bioavailibility and CNS-PK on rodents and non-rodents with a high competence in the study of the Blood Brain Barrier passage.